Todd Bazemore is a biopharmaceutical executive with over 23 years of experience spanning orphan diseases to large primary care conditions. Prior to joining Kala, Todd served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (USA), Inc., where he was instrumental in building the company’s U.S. operations. Prior to Santhera U.S., Todd served as Executive Vice President and Chief Commercial Officer of Dyax Corp. (acquired by Shire Plc), where he was responsible for global commercial strategy and oversight of all commercial functions. Prior to Dyax, Todd was at Sunovion Pharmaceuticals, Inc. (previously Sepracor Inc.), where he served in a variety of Commercial leadership roles of increasing responsibility. Todd has a Bachelor’s of Science in Health from the University of Massachusetts at Lowell.